Cosmetic Surgery and Aesthetic Tourism: The Korean-Adjacent Bangkok Cluster
Thai cosmetic-surgery and aesthetic-medicine market THB ~76.5B forecast 2025 (+2.8% YoY, ArokaGO), part of a broader medical, wellness-tourism market worth USD ~31.5B in 2024 with ~13% CAGR to 2034 (GMI). Clinics dominate (~85% of market value); hospitals (~15%) capture premium tier including Yanhee, Bumrungrad, BDMS-Phyathai 2, BPH Aesthetic, Samitivej, BNH. Foreign patient arrivals to Thai private hospitals reached ~3M in 2024-2025; 79% of procedures now surgical (up from 75% in 2022). Gender-affirming surgery (GRS, SRS) globally recognised β PAI, Kamol, Suporn, Chettawut, Sanguan, Yanhee primary clinics; total packages USD 10,000-25,000 vs USD 30,000-100,000 in the US.
Key takeaways
- 1
Thai cosmetic-surgery, aesthetic-medicine market sized at THB ~ in 2025 (+ YoY, ArokaGO). Broader Thai medical, wellness tourism: USD ~ in 2024, projected to triple by 2034 at ~ CAGR (GMI).
- 2
Channel split: aesthetic clinics ~ of market value (Sukhumvit, Phloen Chit, Thonglor cluster); hospitals ~ (Yanhee, Bumrungrad, BDMS-Phyathai 2, BPH Aesthetic, Samitivej, BNH) capture premium tier.
- 3
of procedures now surgical, up from in 2022. Foreign-patient arrivals to Thai private hospitals reached ~ in 2024-2025. Cosmetic surgery is the #2 most popular service for international patients (after general medical, after orthopaedics).
- 4
Procedure mix: facial injectables (Botox, fillers) ~ by value, rhinoplasty Korean-style high-bridge largest surgical segment, breast augmentation, reduction, liposuction, body contouring, GRS, SRS niche.
- 5
Patient mix: ~ Thai-domestic, ~ Chinese-inbound (recovery from 2020-2022 trough), ~ ASEAN regional, ~ Western. Top inbound markets: China, Malaysia, Japan.
- 6
GRS, SRS specialty internationally recognised; PAI (Preecha Aesthetic Institute, 6,000+ procedures since 1980), Kamol, Suporn (Pattaya), Chettawut, Sanguan (Phuket), Yanhee primary clinics. Packages vs 3-4x in US, UK.
Questions this report answers
How big is the Thai cosmetic-surgery, aesthetic market in 2025? ArokaGO sizes it at THB ~ in 2025, growing + YoY on macro-headwinds (economic challenges, competition, purchasing-power pressure). It sits within the broader Thai medical, wellness tourism market valued at USD ~ in 2024 (Global Market Insights), projected to triple by 2034 at ~ CAGR. Foreign-patient arrivals to Thai private hospitals reached ~ in 2024-2025; cosmetic surgery is the #2 most popular service for international patients after general medical and orthopaedics.[, ]
Who runs Thai cosmetic-surgery, and what's the channel split? Channel split: aesthetic clinics ~ of market value (Bangkok Sukhumvit, Phloen Chit, Thonglor dense cluster); hospitals ~ (Yanhee Hospital ~600 beds dedicated cosmetic, Bumrungrad cosmetic-clinic, BDMS-Phyathai 2, Bangkok Plastic Surgery BPH Aesthetic, Samitivej, BNH, Bangkok Hospital Group) capture premium tier. Hospitals are projected to grow their share modestly thanks to high-acuity international patients seeking accredited facilities.[, , ]
What's the procedure mix? Facial injectables (Botox, dermal fillers, threadlift) form ~ of market by value and are the highest-growth sub-segment. Rhinoplasty Korean-style high-bridge remains the largest surgical category; eyelid surgery, breast augmentation, reduction, liposuction, body contouring, hair transplant FUE are standard. of procedures are now surgical (up from in 2022) thanks to safer technology and shorter-recovery techniques. Thai gender-affirming surgery (GRS, SRS) is a globally recognised specialty.[, ]
What's the patient and pricing structure? Patient mix runs ~ Thai-domestic, ~ Chinese-inbound, ~ ASEAN regional (Malaysia, Singapore, Indonesia, Vietnam), ~ Western (Australia, UK, Northern Europe, US). Thai pricing typically below Singapore, Hong Kong; below US, UK on comparable procedures. GRS, SRS packages run in Thailand vs 3-4x in the US. Chinese-inbound recovery from the 2020-2022 visa trough is the primary 2024-2026 tailwind.[, ]
Executive summary
Thai cosmetic-surgery, aesthetic-medicine market sized at THB ~ in 2025 (+ YoY, ArokaGO). It sits within Thai medical, wellness tourism valued at USD ~ in 2024 (Global Market Insights), projected to triple by 2034 at ~ CAGR. Foreign-patient arrivals to Thai private hospitals reached ~ in 2024-2025; cosmetic surgery is the #2 most popular service for international patients after general medical and orthopaedics.[, ]
Channel split: aesthetic clinics ~ of market value; hospitals ~ (Yanhee ~600 beds dedicated, Bumrungrad cosmetic-clinic, BDMS-Phyathai 2, BPH Aesthetic, Samitivej, BNH) capture premium tier. of procedures now surgical, up from in 2022. Procedure mix: facial injectables (Botox, fillers; ~ by value, highest-growth), rhinoplasty Korean-style largest surgical category, breast augmentation, reduction, liposuction, body contouring, GRS, SRS niche.[, ]
Patient mix: ~ Thai-domestic, ~ Chinese-inbound, ~ ASEAN regional, ~ Western. Pricing below Singapore, Hong Kong; below US, UK. GRS, SRS specialty: PAI (Preecha Aesthetic Institute, 6,000+ procedures since 1980), Kamol, Suporn (Pattaya), Chettawut, Sanguan (Phuket), Yanhee primary clinics; packages Chinese-inbound recovery 2023-2026 tailwind.[, ]
Thai cosmetic-surgery, aesthetic market size (THB billion, 2021-2025E)
2021
Market (THB B)
~45
Context
COVID trough; international travel restricted.
2022
Market (THB B)
~55
Context
Reopening; Chinese-inbound delayed.
2023
Market (THB B)
~65
Context
Chinese visa-free, inbound recovery.
2024
Market (THB B)
~72
Context
~3M foreign patients to private hospitals.
2025E
Market (THB B)
~76.5
Context
ArokaGO forecast; +2.8% YoY.
| Year | Market (THB B) | Context |
|---|---|---|
| 2021 | ~45 | COVID trough; international travel restricted. |
| 2022 | ~55 | Reopening; Chinese-inbound delayed. |
| 2023 | ~65 | Chinese visa-free, inbound recovery. |
| 2024 | ~72 | ~3M foreign patients to private hospitals. |
| 2025E | ~76.5 | ArokaGO forecast; +2.8% YoY. |
Channel mix (% of 2024-2025 market value)
Aesthetic clinics (standalone)
Share %
Notes
Bangkok Sukhumvit, Phloen Chit, Thonglor cluster.
Hospitals (international, premium-tier)
Share %
Notes
Yanhee, Bumrungrad, BDMS-Phyathai 2, BPH, Samitivej, BNH.
| Channel | Share % | Notes |
|---|---|---|
| Aesthetic clinics (standalone) | 85% | Bangkok Sukhumvit, Phloen Chit, Thonglor cluster. |
| Hospitals (international, premium-tier) | 15% | Yanhee, Bumrungrad, BDMS-Phyathai 2, BPH, Samitivej, BNH. |
Patient origin mix (% of 2024-2025 procedure volume)
Thai-domestic
Share %
~53%
Notes
Baseline volume.
Chinese-inbound
Share %
Notes
Recovering from 2020-2022 trough.
ASEAN regional
Share %
~13%
Notes
Malaysia, Singapore, Indonesia, Vietnam.
Western (Australia, UK, EU, US)
Share %
Notes
GRS, SRS, complex rhinoplasty bias.
| Origin | Share % | Notes |
|---|---|---|
| Thai-domestic | ~53% | Baseline volume. |
| Chinese-inbound | ~22% | Recovering from 2020-2022 trough. |
| ASEAN regional | ~13% | Malaysia, Singapore, Indonesia, Vietnam. |
| Western (Australia, UK, EU, US) | ~12% | GRS, SRS, complex rhinoplasty bias. |
Procedure mix (relative ranking, 2024-2025)
Facial injectables (Botox, fillers, threadlift)
Rank
~25-30% by value
Notes
Highest-growth sub-segment; clinic-channel anchor.
Rhinoplasty (Korean-style high-bridge)
Rank
Largest surgical
Notes
K-Beauty pull; Korean-trained surgeons.
Breast augmentation, reduction
Rank
Material
Notes
Domestic, Chinese, ASEAN drivers.
Liposuction, body contouring
Rank
Material
Notes
Cool-sculpting, RF energy devices.
GRS, SRS (gender-affirming)
Rank
Niche, premium
Notes
Internationally recognised specialty.
Hair transplant (FUE)
Rank
Niche, growing
Notes
Male-pattern baldness; Thai, Asian patients.
| Procedure | Rank | Notes |
|---|---|---|
| Facial injectables (Botox, fillers, threadlift) | ~25-30% by value | Highest-growth sub-segment; clinic-channel anchor. |
| Rhinoplasty (Korean-style high-bridge) | Largest surgical | K-Beauty pull; Korean-trained surgeons. |
| Breast augmentation, reduction | Material | Domestic, Chinese, ASEAN drivers. |
| Liposuction, body contouring | Material | Cool-sculpting, RF energy devices. |
| GRS, SRS (gender-affirming) | Niche, premium | Internationally recognised specialty. |
| Hair transplant (FUE) | Niche, growing | Male-pattern baldness; Thai, Asian patients. |
Analyst framing
Why this report matters
Unlock the full report
Need more than the web report? Ask for a scoped export or source appendix.
Every report keeps visible citations and source metadata. Terms.
Related reports
Thai Medical Tourism: Acuity Mix and the International-Cohort Recovery
Thai medical tourism splits cleanly across acuity tiers: high-acuity cardiology, oncology and orthopaedics (Middle East and CLMV led, ~38% of international revenue), mid-acuity cosmetic and gynaecology (~26%), wellness, IVF and executive (~20%), and dental, check-up and day-case (~16%). BDMS, Bumrungrad and Bangkok Chain Hospital capture the bulk of high-spend international flow at JCI-accredited price points roughly 30-50% below US, UK and Singapore equivalents, with the 2024 recovery led by the Middle East cohort while Chinese flow recovers more slowly.
Open report β
Thailand Cosmetic Surgery & Aesthetic Medicine Market Intelligence
Thailand cosmetic surgery and aesthetic medicine reached an estimated THB 76.5B (~USD 2.1B) in 2025 per Kasikorn Research (+2.8% YoY), with Grand View Research projecting an 11.6% CAGR through 2030 on a USD 1.46B 2023 device-and-procedure baseline. Surgical hospital cluster is anchored by BDMS (Bangkok Hospital aesthetic, BDMS Wellness Clinic, Phyathai-Paolo), Bumrungrad (Esperance, Vitallife), MedPark, and a deep specialist bench in Yanhee, Bangkok Plastic Surgery, and Phyathai 2. The non-invasive device segment runs across ~7,000 aesthetic clinics (Wuttisak, Apex, Pongsak, Nida, Rajdhevee) deploying Hydrafacial, Pico laser, Thermage, and Ultherapy. Gender-affirming surgery (Yanhee, Suporn, Kamol, PAI, Chettawut, Sanguan) is an internationally recognised specialty. Source-country mix is rebalancing from China toward GCC, Australia, US, and Europe; the LTR Long-Term Resident visa supports wellness-medical residency. Korean medical-tourism competition is intensifying as Korea crossed 130,000 aesthetic patients in 2024.
Open report β
Thai Aging Population: Pension Reform and the Private-Healthcare Demand Curve
Thailand officially entered complete aged-society status in 2021 with people aged 60+ comprising 20% of the population per Krungsri Research; the proportion is projected to reach 30% by 2030. The UN expects 65+ to exceed 20% of population by 2029 β Thailand will then qualify as super-aged. Pension reform is in motion: a Royal Decree on 15 November 2024 created the Employee Welfare Fund (EWF) β a new supplementary provident-fund programme launched 1 October 2025 per the US SSA International Update. The Office of the Civil Service Commission is conducting a feasibility study to extend civil-servant retirement age from 60 to 65 per Nation Thailand and Pension Policy International. Per the JIL Thailand seminar paper, Thailand needs inclusive labour-reform to maintain workforce participation as the demographic transition advances. WHO Thailand supports long-term-care financing and home-based-care models. The Social Security Fund's pension benefits are structurally insufficient for retired-worker income replacement; nearly half the population works in the informal sector and lacks effective pension coverage. The structural-investor read: SET-listed hospital groups (BDMS, Bumrungrad International) face structural demand tailwind from private-healthcare aging-population spend; long-term-care insurance market is structurally underdeveloped β material 2026-2030 growth opportunity.
Open report β
BCH Bangkok Chain Hospital: Mid-Market Positioning and IPO Aftermath
BCH (SET: BCH) booked THB 11.83B revenue and THB 1.28B net profit in FY2024 across 16 hospitals plus 2 polyclinics (2,323 licensed beds). The franchise sits between BDMS premium (59 hospitals, 8,841 beds) and government tier, with c.7.7% share of the Social Security Office (SSO) private-hospital patient base β roughly one-third of revenue from SSO contracts. Twenty-one years post-2004 SET listing, the strategic question is whether Kasemrad mid-market scale can compound margin without conceding the SSO franchise.
Open report β